%0 Journal Article
%T A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol
%A Fumihiko Yasuno
%A Haruko Yamamoto
%A Hidenao Fukuyama
%A Kazuyuki Nagatsuka
%A Masanori Fukushima
%A Naoya Oishi
%A Ryosuke Kakuta
%A Satoshi Saito
%A Shinsuke Kojima
%A Takakuni Maki
%J Archive of "Alzheimer's & Dementia : Translational Research & Clinical Interventions".
%D 2016
%R 10.1016/j.trci.2016.10.001
%X There are currently no effective treatments preventing conversion from mild cognitive impairment (MCI) to Alzheimer's disease. Cilostazol is a selective type-3 phosphodiesterase inhibitor that ameliorates accumulation of amyloid-¦Â and has prevented cognitive decline in rodent models. Furthermore, cilostazol is known to suppress platelet aggregation, protect vascular endothelia, dilate vessels, and increase cerebral blood flow. Beneficial effects have also been shown in observational cohort studies, demonstrating the need for a prospective clinical trial
%K Alzheimer's disease
%K Cilostazol
%K Clearance
%K Clinical trial
%K Drug repositioning
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651350/